Patient Deaths Cited as Darzalex Combination Trials Halted

Genmab has acknowledged that its development partner for Darzalex ® (daratumumab), Johnson & Johnson’s Janssen Biotech, will halt two clinical trials assessing combinations of the drug with two other cancer treatments—with one combination linked to more deaths in multiple myeloma.That combination—Darzalex plus Genentech’s anti-programmed death-ligand 1 (anti-PD-L1) antibody Tecentriq ®(atezolizumab)—has been the subject of CALLISTO/LUC2001 ( NCT03023423